Translating Viral Vector Vaccine Success to Gene Therapy Advancements
Time: 12:00 pm
day: Day One
Details:
- Leveraging J&J’s decade of experience in optimising viral vector formulations, improving stability and enhancing the efficacy of gene therapy products
- Adapting novel analytical techniques from viral vector vaccine work to develop robust, scalable methods tailored to gene therapy needs
- Using predictive modelling and cutting-edge strategies from vaccine development to mitigate risks and ensure product consistency in gene therapy
